Latest Insider Transactions at Akoya Biosciences, Inc. (AKYA)
This section provides a real-time view of insider transactions for Akoya Biosciences, Inc. (AKYA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Akoya Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Akoya Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 08
2025
|
John Frederick Ek CFO |
SELL
Other acquisition or disposition
|
Indirect |
20,000
-100.0%
|
-
|
|
Jul 08
2025
|
John Frederick Ek CFO |
SELL
Other acquisition or disposition
|
Direct |
248,202
-60.97%
|
-
|
|
Jul 08
2025
|
Jennifer Kamocsay Chief Legal Officer |
SELL
Other acquisition or disposition
|
Direct |
179,272
-54.68%
|
-
|
|
Jul 08
2025
|
Brian Mc Kelligon President and CEO |
SELL
Other acquisition or disposition
|
Direct |
947,688
-100.0%
|
-
|
|
Jul 08
2025
|
Brian Mc Kelligon President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
196,866
-17.2%
|
-
|
|
Jul 08
2025
|
Brian Mc Kelligon President and CEO |
BUY
Other acquisition or disposition
|
Direct |
724,428
+27.52%
|
-
|
|
Jul 08
2025
|
Niro Ph.D Ramachandran Chief Business Officer |
SELL
Other acquisition or disposition
|
Direct |
282,555
-76.89%
|
-
|
|
Jul 08
2025
|
Niro Ph.D Ramachandran Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
42,148
-12.98%
|
-
|
|
Jul 08
2025
|
Niro Ph.D Ramachandran Chief Business Officer |
BUY
Other acquisition or disposition
|
Direct |
62,566
+16.16%
|
-
|
|
Jul 08
2025
|
Scott Mendel Director |
SELL
Other acquisition or disposition
|
Direct |
28,500
-100.0%
|
-
|
|
Jul 08
2025
|
Goldman Myla Lai Director |
SELL
Other acquisition or disposition
|
Direct |
20,000
-100.0%
|
-
|
|
Jul 08
2025
|
Thomas A. Raffin Director |
SELL
Other acquisition or disposition
|
Indirect |
17,909,839
-100.0%
|
-
|
|
Jul 08
2025
|
Matthew Winkler Director |
SELL
Other acquisition or disposition
|
Direct |
984,513
-100.0%
|
-
|
|
Jul 08
2025
|
Pascal Bamford Chief Clinical Officer |
SELL
Other acquisition or disposition
|
Direct |
205,738
-52.31%
|
-
|
|
Jun 01
2025
|
Pascal Bamford Chief Clinical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
670
-0.32%
|
$670
$1.25 P/Share
|
|
Apr 01
2025
|
John Frederick Ek CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,432
-6.21%
|
$16,432
$1.35 P/Share
|
|
Mar 23
2025
|
Niro Ph.D Ramachandran Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,310
-0.8%
|
$2,310
$1.7 P/Share
|
|
Mar 23
2025
|
Brian Mc Kelligon President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,550
-1.77%
|
$7,550
$1.7 P/Share
|
|
Mar 01
2025
|
Jennifer Kamocsay Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,445
-2.01%
|
$7,445
$1.63 P/Share
|
|
Mar 01
2025
|
John Frederick Ek CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,594
-1.34%
|
$3,594
$1.63 P/Share
|
|
Mar 01
2025
|
Pascal Bamford Chief Clinical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,850
-0.92%
|
$3,850
$1.63 P/Share
|
|
Mar 01
2025
|
Niro Ph.D Ramachandran Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,904
-1.0%
|
$5,904
$1.63 P/Share
|
|
Mar 01
2025
|
Brian Mc Kelligon President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,807
-1.8%
|
$15,807
$1.63 P/Share
|
|
Nov 19
2024
|
Pascal Bamford Chief Clinical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
87,500
+29.39%
|
-
|
|
Nov 19
2024
|
John Frederick Ek CFO |
BUY
Grant, award, or other acquisition
|
Direct |
87,500
+24.6%
|
-
|
|
Nov 19
2024
|
Jennifer Kamocsay Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
87,500
+31.91%
|
-
|
|
Nov 19
2024
|
Brian Mc Kelligon President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
218,750
+33.03%
|
-
|
|
Nov 19
2024
|
Niro Ph.D Ramachandran Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
87,500
+22.85%
|
-
|
|
Aug 29
2024
|
Pascal Bamford Chief Clinical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+24.58%
|
-
|
|
Jun 11
2024
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
7,500
-3.23%
|
$15,000
$2.08 P/Share
|
|
Jun 11
2024
|
Brian Mc Kelligon President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+3.13%
|
$0
$0.3 P/Share
|
|
Jun 06
2024
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
7,500
-3.23%
|
$15,000
$2.01 P/Share
|
|
Jun 06
2024
|
Brian Mc Kelligon President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+3.13%
|
$0
$0.3 P/Share
|
|
Apr 01
2024
|
John Frederick Ek CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
14,272
-7.32%
|
$57,088
$4.56 P/Share
|
|
Mar 23
2024
|
Niro Ph.D Ramachandran Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,006
-0.96%
|
$8,024
$4.79 P/Share
|
|
Mar 23
2024
|
Frederic Pla Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,006
-1.94%
|
$8,024
$4.79 P/Share
|
|
Mar 23
2024
|
Brian Mc Kelligon President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,135
-3.08%
|
$28,540
$4.79 P/Share
|
|
Mar 20
2024
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
7,500
-3.13%
|
$30,000
$4.97 P/Share
|
|
Mar 20
2024
|
Brian Mc Kelligon President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+3.04%
|
$0
$0.3 P/Share
|
|
Mar 13
2024
|
Robert G Shepler Director |
BUY
Bona fide gift
|
Indirect |
369,592
+50.0%
|
-
|
|
Mar 13
2024
|
Robert G Shepler Director |
SELL
Bona fide gift
|
Indirect |
369,592
-100.0%
|
-
|
|
Mar 13
2024
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
7,500
-3.23%
|
$30,000
$4.94 P/Share
|
|
Mar 01
2024
|
Niro Ph.D Ramachandran Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,305
-1.09%
|
$13,830
$6.03 P/Share
|
|
Mar 01
2024
|
Frederic Pla Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,049
-1.94%
|
$12,294
$6.03 P/Share
|
|
Mar 01
2024
|
Jennifer Kamocsay Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,283
-3.2%
|
$19,698
$6.03 P/Share
|
|
Mar 01
2024
|
Brian Mc Kelligon President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,244
-2.68%
|
$61,464
$6.03 P/Share
|
|
Feb 22
2024
|
John Frederick Ek CFO |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+15.22%
|
-
|
|
Feb 22
2024
|
Niro Ph.D Ramachandran Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+14.16%
|
-
|
|
Feb 22
2024
|
Frederic Pla Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+24.9%
|
-
|
|
Feb 22
2024
|
Jennifer Kamocsay Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+25.45%
|
-
|